الفهرس 
AcknowledgementsOnly 14 pages are availabe for public view
 |  | from | 148 |  |  |
| | | from | 148 | | |
Abstract
This is a retrospective study on 148 patients with epithelial ovarian cancer who attended to Clinical Oncology & Nuclear Medicine Department, Mansoura University Hospital during the period from January 2009 up to December 2013. This study assessed clinico- epidemiologic parameters of EOC and evaluated progression free survival (PFS) and overall survival (OS). It also identified prognostic factors affecting PFS and OS and toxicity profile of chemotherapeutic agents used in treatment of EOC. It was found that the median age was 55 years old with a range 19 to 80 years, while the mean age was 53.8 ± 12.2 years. Positive family history of ovarian, breast, or colon cancer was found to be 12.2% of all patients. Serous carcinoma was the predominant histopathological subtypes followed by endometroid subtype. Typical presentation was late for all patients in the current study. Stage III and IV predominated. Most of our patients were treated initially with surgery followed by adjuvant chemotherapy. Paclitaxel- carboplatin regimen was the most common chemotherapy used. Survival analysis for all cases of EOC showed that median overall survival was 49 months, while, median PFS was 18 months. The 5 years overall survival for all patients was 37%.